EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study

Alex Jaimes iD, Jaime Rodríguez-Vico, Olga Pajares, Ignacio Eguilior Caffarena, Anna Lena Nystrom Hernández, Andrea Gómez, Jesús Porta-Etessam iD

Cephalalgia · 2025

DOI: 10.1177/03331024251346925 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cephalalgia, 2025. Verfasst von Alex Jaimes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Headache Unit, Neurology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A subset of individuals with episodic migraine (EM) and chronic migraine (CM) does not respond to anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), even after switching agents. Although atogepant is effective in EM and CM, its role in individuals unresponsive to anti-CGRP mAbs remains to be elucidated. We hypothesize that atogepant may be a viable preventive option in these cases.

Methods

We conducted a retrospective cohort study in EM and CM individuals who discontinued anti-CGRP mAbs due to lack or loss of efficacy and were subsequently treated with atogepant. The primary endpoint was the ≥50% response rate in monthly headache days (MHDs). Secondary outcomes included ≥30% and ≥75% response rates in MHDs, response rates in monthly moderate-to-severe headache days (MSHDs), and changes in MHDs, MSHDs, acute medication days (AMDs) and Headache Impact Test (HIT-6). Patient Global Impression (PGI) scores and adverse events (AEs) were recorded.

Results

Of 213 screened records, 44 participants met inclusion criteria; 39 (88.6%) were female and 39 (88.6%) had CM. Prior use of anti-CGRP mAbs included erenumab in 11.4% of participants, galcanezumab in 52.3% and fremanezumab in 86.3%. After three months, 18.2% achieved a ≥50% reduction in MHDs; ≥30% and ≥75% response rates were 25.0% and 6.8% respectively. For MSHDs, ≥30%, ≥50% and ≥75% response rates were 47.6%, 33.3% and 19.0%, respectively. Median MHDs decreased from 24.5 (interquartile range (IQR) = 16.0–30.0; range 9.0–31.0) to 21.5 (IQR = 10.0–30.0; range 3.0–31.0; p = 0.011), and median MSHDs from 15.0 (IQR = 10.0–25.5; range 5.0–30.0) to 12.0 (IQR = 5.9–19.0; range 0.0–30.0; p = 0.001). AMDs and HIT-6 scores also showed significant reductions. According to the PGI scale, 59.1% of individuals reported some degree of improvement. AEs occurred in 50.0% of participants, most commonly constipation (31.8%). Five (11.4%) participants discontinued treatment due to side effects.

Conclusions

After three months of treatment, atogepant led to a clinically meaningful improvement in a subset of participants. It may be a valuable preventive option for individuals unresponsive to anti-CGRP mAbs and warrants further investigation in prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related PeptideAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemaleRetrospective StudiesMaleAdultMiddle AgedCohort StudiesTreatment Outcome

Stichwörter der Autor:innen

evidencegepantreal-worldresistanttreatment

Substanzen

Calcitonin Gene-Related PeptideAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Headache Unit, Neurology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • School of Medicine, Autonomous University of Madrid, Madrid, Spain.

ORCID-Profile: Alex Jaimes, Jesús Porta-Etessam

Zitieren

APA

Jaimes, A., Rodríguez-Vico, J., Pajares, O., Eguilior Caffarena, I., Nystrom Hernández, A. L., Gómez, A., & Porta-Etessam, J. (2025). Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study. Cephalalgia. https://doi.org/10.1177/03331024251346925

Vancouver

Jaimes A, Rodríguez-Vico J, Pajares O, Eguilior Caffarena I, Nystrom Hernández AL, Gómez A, et al. Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study. Cephalalgia. 2025. doi:10.1177/03331024251346925

BibTeX
@article{Jaimes2025,
  author = {Jaimes, Alex and Rodríguez-Vico, Jaime and Pajares, Olga and Eguilior Caffarena, Ignacio and Nystrom Hernández, Anna Lena and Gómez, Andrea and Porta-Etessam, Jesús},
  title = {Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study},
  journal = {Cephalalgia},
  year = {2025},
  doi = {10.1177/03331024251346925}
}
Kostenlos starten →